Login / Signup

Early diagnosis of secondary progressive multiple sclerosis: focus on fluid and neurophysiological biomarkers.

Gina FerrazzanoSebastiano Giuseppe CrisafulliViola BaioneMatteo TartagliaAntonio CorteseMarco FrontoniMarta AltieriFlavia PauriEnrico MillefioriniAntonella Conte
Published in: Journal of neurology (2020)
To date, no neurophysiological or fluid biomarker is sufficiently validated to support the early diagnosis of SPMS. Neurophysiological measurements, including short interval intracortical inhibition and somatosensory temporal discrimination threshold, and the neurofilament light chain fluid biomarker seem to be the most promising. Cross-sectional studies on an adequate number of patients followed by longitudinal studies are needed to confirm the diagnostic and prognostic value of these biomarkers. A combination of neurophysiological and fluid biomarkers may be more sensitive in detecting SPMS conversion.
Keyphrases
  • multiple sclerosis
  • cross sectional
  • end stage renal disease
  • ejection fraction
  • chronic kidney disease
  • newly diagnosed
  • prognostic factors
  • peritoneal dialysis
  • case control
  • white matter
  • cerebrospinal fluid